Trade bluebird bio, Inc. - BLUE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.19 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.86 |
| Open | 4.78 |
| 1-Year Change | 285.48% |
| Day's Range | 4.78 - 5.25 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 4.86 | 0.46 | 10.45% | 4.40 | 5.38 | 4.25 |
| Mar 28, 2025 | 4.06 | 0.47 | 13.09% | 3.59 | 4.31 | 3.59 |
| Mar 27, 2025 | 3.76 | 0.07 | 1.90% | 3.69 | 3.79 | 3.62 |
| Mar 26, 2025 | 3.72 | -0.09 | -2.36% | 3.81 | 3.81 | 3.66 |
| Mar 25, 2025 | 3.87 | 0.03 | 0.78% | 3.84 | 3.89 | 3.79 |
| Mar 24, 2025 | 3.84 | 0.06 | 1.59% | 3.78 | 3.93 | 3.78 |
| Mar 21, 2025 | 3.84 | 0.02 | 0.52% | 3.82 | 3.97 | 3.78 |
| Mar 20, 2025 | 3.94 | 0.17 | 4.51% | 3.77 | 3.97 | 3.74 |
| Mar 19, 2025 | 3.87 | 0.02 | 0.52% | 3.85 | 3.94 | 3.74 |
| Mar 18, 2025 | 3.84 | 0.03 | 0.79% | 3.81 | 3.97 | 3.77 |
| Mar 17, 2025 | 3.92 | 0.22 | 5.95% | 3.70 | 3.99 | 3.64 |
| Mar 14, 2025 | 3.73 | 0.03 | 0.81% | 3.70 | 3.79 | 3.64 |
| Mar 13, 2025 | 3.66 | -0.10 | -2.66% | 3.76 | 3.80 | 3.63 |
| Mar 12, 2025 | 3.84 | -0.06 | -1.54% | 3.90 | 3.93 | 3.73 |
| Mar 11, 2025 | 3.89 | 0.07 | 1.83% | 3.82 | 4.07 | 3.79 |
| Mar 10, 2025 | 3.89 | 0.00 | 0.00% | 3.89 | 4.02 | 3.82 |
| Mar 7, 2025 | 3.99 | 0.05 | 1.27% | 3.94 | 4.11 | 3.90 |
| Mar 6, 2025 | 4.01 | 0.16 | 4.16% | 3.85 | 4.12 | 3.84 |
| Mar 5, 2025 | 3.96 | 0.15 | 3.94% | 3.81 | 4.03 | 3.74 |
| Mar 4, 2025 | 3.83 | 0.02 | 0.52% | 3.81 | 3.94 | 3.71 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Bluebird Company profile
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.| Industry: | Bio Therapeutic Drugs |
455 Grand Union Boulevard
SOMERVILLE
MASSACHUSETTS 02145
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com